Document Detail

The Optimal Treatment of Thyroid Gland Function Disturbances During Pregnancy.
MedLine Citation:
PMID:  21342119     Owner:  NLM     Status:  Publisher    
Thyroid disorders are quite a common health problem in pregnant women, thus adequate treatment in this period is very important in order to decrease maternal and fetal morbidity. The prevalence of hyperthyroidism is estimated to be present in approximately 0.2-0.4% of all pregnancies and the most common is Graves disease. Untreated hyperthyroidism is connected with disturbed fertilisation, recurrent miscarriages, preeclampsia development, hypotrophy of the fetus, and haemorrhage in the postpartum period. Hypothyroidism is found in pregnant women in 0.3-0.7% of all cases. Uncontrolled hypothyroidism in pregnancy can lead to preterm birth, low birth weight and mental retardation. The goal of the treatment of both hypo- and hyperthyroidism is to reach a stable euthyroid state by applying thyroid hormones or antithyroid drugs, respectively. It seems that well-controlled management of thyroid diseases does not pose any problem for pregnancy. However, the most important is to avoid any neurological abnormalities in the fetus in hyperthyroid women resulting from antithyroid drugs exposure. Moreover, it is also crucial to abstain from subclinical hypothyroidism and hypothyroxinaemia in the mother and its effect on the fetus's development which merits exact screening and intense monitoring. In this paper we described the complex pharmacology of the drugs that are used in pregnant women suffering from thyroid disorders, considering the clinical application, practical recommendation, and side effects in pregnancy and lactation. This systematic analysis could contribute some pharmacological knowledge which will be helpful in the clinical management of thyroid disorders during pregnancy.
Krzysztof Drews; Agnieszka Seremak-Mrozikiewicz
Related Documents :
6153239 - Fetal-maternal bleeding associated with genetic amniocentesis.
23040139 - Advance supply of emergency contraception: a systematic review.
6180779 - Statistical methods for fetal monitoring with alpha-fetoprotein in maternal serum.
21477329 - The rapid growth of a pleomorphic adenoma of the parotid gland in the third trimester o...
2454079 - Regulators of fetal liver differentiation in vitro.
7625759 - Prevalence of neural tube defects in northeastern france, 1979-1992 impact of prenatal ...
15304599 - Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study.
6546579 - Circulating lymphocyte subpopulations in pregnancy: a longitudinal study.
25081349 - Fetal growth in relation to gestational weight gain in women with type 2 diabetes: an o...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-2-22
Journal Detail:
Title:  Current pharmaceutical biotechnology     Volume:  -     ISSN:  1873-4316     ISO Abbreviation:  -     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-2-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100960530     Medline TA:  Curr Pharm Biotechnol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Division of Perinatology and Women's Diseases, Department of Perinatology and Gynecology, University of Medical Sciences, Polna Street 33, 60-535 Poznan, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antiepileptic Drugs During Pregnancy: Pharmacokinetics and Transplacental Transfer.
Next Document:  Transplacental Transfer of Immunosuppressants and Biologics Used for the Treatment of Inflammatory B...